|
ABSTRACT
The wide spectrum of available in
vivo nuclear medicine methods for infection and inflammation detection
is presented. Some of them are already in use (Tc-nanocolloids,
In-HIG,
67Ga-citrate, Tc-
HMPAO-leukocytes, 111In-oksine-granulocytes, Tc-antigranulocyte
antibodies, antigranulocyte antibody phragments: Tc-LeukoScan,
F-FDG,
etc.), while the others are still in the phase of investigation,
improvement, or clinical trials labelled inflammation mediators:
cytokines (Il-1ra, IL-1alpha, IL-1beta, IL-2, IL-12p40, itd.), hemotactic
peptides (IL-8), ciprofloxacine derivatives (Infecton), antimicrobial
peptides (UBI 18-35, UBI 29-41, UBI 23-35), monoclonal antibody
against CD15 antigens on human neutrophils (LeuTech); Tc-P483H,
labelled liposomes, itd.C.
Availability of the radiopharmaceuticals and nuclear-medicine equipment,
radiation exposure of the patient, clinical situation, the baseline
pathophysiology of a process, and costs are the factors which contribute
to the choice of the diagnostic approach.
In order to ease the choice of the appropriate diagnostic method
for infection/inflammation detection in different clinical situations,
the recommendations from the ISORBE (International Society of Radiolabelled
Blood Elements) meeting in France (Bordeaux, 6-9.9.2000.) are quoted.
Keywords: radiopharmaceuticals,
diagnostic use, infection/radionuclide imaging, inflammation/radio-
nuclide imaging, in vivo diagnostics, nuclear medicine
|
